The reduction of radiation mucositis by selective decontamination antibiotic pastilles: a placebo-controlled double-blind trial
1996

Reducing Radiation Mucositis with Antibiotic Pastilles

Sample size: 275 publication Evidence: moderate

Author Information

Author(s): RP Symonds, P Mcllroy, J Khorramil, J Paul, E Pyperl, SR Alcock, I McCallum, ABJ Speekenbrink, A McMurray, E Lindemann, M Thomas

Primary Institution: Beatson Oncology Centre; Department of Clinical Microbiology, Western Infirmary; Royal Naval Hospital, Haslar

Hypothesis

The more severe forms of irradiation mucositis are associated with abnormal carriage of AGNB and yeasts, and selective reduction of these microbial populations with non-absorbable antibiotics would reduce both the signs and symptoms of mucositis.

Conclusion

The study found that antibiotic pastilles reduced mucositis distribution, area, dysphagia, and weight loss in patients undergoing radiotherapy for head and neck cancer.

Supporting Evidence

  • 36% of patients in the active arm developed intermediate or thick pseudomembranes compared to 48% in the placebo arm.
  • There was a significant reduction in mucositis distribution (P=0.002) and area (P=0.028) in the active arm.
  • Patients taking the active pastilles experienced less dysphagia (P=0.006) and weight loss (P=0.009).
  • The active pastilles significantly reduced the percentage of patients with yeast cultures (P=0.003).

Takeaway

Doctors tested if special candy could help patients with mouth sores from radiation treatment. The candy helped make the sores less painful and reduced weight loss.

Methodology

Patients were randomly assigned to receive either antibiotic pastilles or a placebo, and their mucositis symptoms were monitored during radiotherapy.

Potential Biases

The double-blind nature of the study suggests minimal bias, but the exclusion of unevaluable patients could introduce some bias.

Limitations

The study had a slight imbalance in the site of disease and a significant number of patients were unevaluable.

Participant Demographics

Patients with T-4 head and neck cancer undergoing radical radiotherapy, with a median age of 62 years.

Statistical Information

P-Value

0.009

Confidence Interval

95% CI 0.89-2.82

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication